Ambalal Sarabhai Enterprise Ltd
Add to watch list to get report alerts
BSE Code:
500009
NSE Code:
AMBASARABH
Business Profile
Business Profile
Ambalal Sarabhai Enterprises Ltd (ASEL) was incorporated on 27th June 1977, as a private limited company. It was converted into a public limited company on 29th December 1980. The business of the company is manufacture of drugs and pharmaceuticals, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials. The Company also carries on industrial research and consultancy services.
ASEL has major presence in anti-infectives, anti-epileptic and NSAID`s(Non-Steroidal Anti- Inflammatory Drugs) . The company is the largest manufacturer of Vitamin C in India. ASEL is the market leader in Veterinary healthcare sector.
ASEL has aggressively formed alliances in the last couple of years to leverage upon the technical expertise and strong brands. On domestic front the company has formed 50:50 JV to market the brands. The company has tied up with BV Chiron, Netherlands for marketing anti-cancer products in India, Grunenthal of Germany to manufacture and market Tramadol (an analgesic), with Biobrass of Brazil for the marketing of procine and insulin and with Abic of Israel for the marketing of poultry vaccines in India.
It has also set up a joint-venture withCadila Healthcare of the Zydus Group, to set up a company in the animal healthcare sector.The joint venture company is known as `Sarabhai Zydus Animal Health Ltd`.
Recent Developments
ASEL is pursuing major restructuring program and to further strategic alliances and collaborations, the company has appointed Pricewaterhouse Coopers as Consultant. With commitment of the management to turnaround the company through alliances, restructuring of operations and cutting down the high cost debt, ASEL is expected to improve profitability in the next two years.
Future Plans
To expand the market for its products, the company is negotiating with some overseas parties who would provide necessary technology as also buy-back arrangements of the products manufactured. Upon finalisation and implementation of such arrangement, it is expected that there would be considerable increase in the volume of the bulk drug business and increase in profits.